For decades, the clinical focus of treating Major Depressive Disorder has been on alleviating profound sadness. However, traditional monoaminergic antidepressants often fall short of treating anhedonia—the absolute absence of pleasure—and can even cause "emotional blunting" by placing an artificial ceiling on a patient's dopamine-driven joy. In Episode 58, we explore a landmark 2026 systematic review by Faisal and colleagues that synthesizes 13 neuroimaging studies to show how ketamine acts not just as an antidepressant, but as a "pro-joy intervention."

We break down the brain's reward architecture into the "Engine" (primitive structures like the striatum and nucleus accumbens) and the "Steering Wheel" (the prefrontal cortex). Chronic depression causes the dendritic spines connecting these regions to wither, leaving the engine dead. But the neuroimaging data is staggering: functional MRI (fMRI) measuring the BOLD signal during the Monetary Incentive Delay task shows that ketamine rapidly reactivates the striatum's response to reward anticipation.

We also dive into PET scan data, revealing how ketamine modulates the 5-HT1B serotonin receptor—acting like a "bouncer" to remove the brakes from the dopamine system. Ultimately, this episode offers profound vindication for patients stuck in the gray zone: anhedonia is not a moral failing or a psychological attitude, but a physical deficit in the brain's wiring that ketamine is structurally capable of repairing.

Reference:

Faisal, H., Le, G. H., Kwan, A. T. H., Wong, S., Cheung, W., Dri, C. E., Cao, B., Rhee, T. G., Bargiota, S., Lo, H. K. Y., Shen, B., Guillen-Burgos, H. F., & McIntyre, R. S. (2026). Effect of ketamine on reward processing in depressive disorders: A systematic review of neuroimaging studies. CNS Spectrums. https://doi.org/10.1017/S109285292610087X